NEW Advances in Cancer Immunotherapy: Translating Discoveries into Clinical Applications
This event is hosted by the Chinese American Hematologist and Oncologist Network (CAHON) and the Journal of Hematology and Oncology (JHO). Held in conjunction with the American Society of Clinical Oncology’s (ASCO) annual meeting, this CME event will educate healthcare providers about the latest advances in immunotherapy research and its growing impact on cancer treatment. By fostering collaboration and knowledge exchange, this gathering aims to accelerate the translation of discoveries into real-world applications, ultimately improving cancer care. (Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation)
Program Agenda | Meeting Organizers | About CAHON | About the JHO
Date & Venue
Friday, May 30, 2025
6:00 - 9:00 pm
Hyatt Regency McCormick Place
2233 S Martin Luther King Dr.
Chicago, IL 60616
CME Session Agenda
2 hours of AMA PRA Category 1 Credit(s)™
6:00 – 6:30 pm Doors and Registration Open, Networking, Dinner Buffet Ready
6:30 – 6:45 pm Opening Remarks
Liang Deng, MD, PhD – CAHON President, Memorial Sloan Kettering Cancer Center
Delong Liu, MD, PhD - Editor-in-Chief, Journal of Hematology & Oncology, New York Medical College
6:45 - 7:15 pm Next Generation T-Cell Therapies for Cancer
Patrick Hwu, MD - President and CEO of Moffitt Cancer Center
7:15 - 7:45 pm Innovations in Cancer Immunotherapy: Overcoming Resistance through Combination Strategies
Jedd D. Wolchok, MD, PhD, FAACR, FASCO - Director of the Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine
7:45 – 8:15 pm Reprogramming the Tumor Microenvironment for Pancreatic Cancer Immunotherapy: Challenges and Opportunities
Lei Zheng, MD, PhD - Executive Director of Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center
8:15 – 8:45 pm Androgen-Mediated CD8+ T Cell Exhaustion: Unveiling Sex Bias in Cancer Immunotherapy
Zihai Li, MD, PhD - Klotz Memorial Chair in Cancer Research, Professor and Founding Director of the Pelotonia Institute for
Immuno-Oncology at The Ohio State University
8:45 - 9:00 pm Closing Remarks
Jing-Zhou Hou, MD, PhD – CAHON Board Chair, University of Pittsburgh Medical Center
*Food and drinks will be provided throughout the event
Meeting Organizers
Liang Deng, MD, PhD – CAHON President, Memorial Sloan Kettering Cancer Center
Jing-Zhou Hou, MD, PhD – CAHON Board Chair, University of Pittsburgh Medical Center
Delong Liu, MD, PhD - Editor-in-Chief, Journal of Hematology & Oncology, New York Medical College
Cynthia Ma, MD, PhD - Washington University
Bo Wang, MD - Willamette Valley Cancer Institute
Yucai Wang, MD, PhD - Mayo Clinic
About CAHON
The Chinese American Hematologist and Oncologist Network (CAHON) is a professional organization committed to fostering collaboration, education, and career development among Chinese American hematologists, oncologists, and cancer researchers. Founded in 2005, CAHON enhances communication among medical professionals, advances high-quality care for patients with neoplastic and hematological diseases, and promotes medical knowledge exchange between the United States and China.
Guided by its 2024-2027 Strategic Plan, CAHON is strengthening global partnerships, expanding its impact on patient care, and enhancing career development opportunities for its members. The organization is also deepening engagement with key stakeholders to foster a more connected and influential oncology community. Through these initiatives, CAHON remains dedicated to advancing scientific progress, improving patient outcomes, and shaping the future of hematology and oncology.
About the Journal of Hematology & Oncology
Official Journal of CAHON | Impact Factor: 29.9
Founded by Professor Delong Liu in 2004, the Journal of Hematology & Oncology is a premier open-access journal providing a platform for high-quality research in hematology and oncology. Recognized as a leading publication in both fields, it ranks in the top quartile (Q1) with a strong impact factor. In addition to original research, the journal features expert reviews and research highlights from leading experts in the field. With a commitment to rapid dissemination, it ensures fast turnaround times, making cutting-edge findings accessible to laboratory scientists, physician-scientists, hematologists, and oncologists worldwide.